Invesco Ltd. boosted its holdings in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 6.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 258,520 shares of the company's stock after purchasing an additional 16,717 shares during the period. Invesco Ltd. owned about 0.46% of Astrana Health worth $8,151,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of ASTH. Stifel Financial Corp acquired a new position in Astrana Health during the third quarter worth $800,000. Barclays PLC bought a new position in Astrana Health during the 3rd quarter valued at about $4,457,000. Franklin Resources Inc. bought a new position in Astrana Health during the 3rd quarter valued at about $1,187,000. Principal Financial Group Inc. acquired a new position in Astrana Health in the third quarter valued at about $13,383,000. Finally, Linden Thomas Advisory Services LLC grew its stake in Astrana Health by 23.3% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 15,247 shares of the company's stock worth $481,000 after buying an additional 2,883 shares during the last quarter. 52.77% of the stock is currently owned by institutional investors.
Astrana Health Trading Down 2.5 %
NASDAQ ASTH traded down $0.80 during trading hours on Friday, hitting $30.60. The company's stock had a trading volume of 206,961 shares, compared to its average volume of 277,952. Astrana Health, Inc. has a twelve month low of $23.12 and a twelve month high of $63.20. The firm has a market capitalization of $1.53 billion, a P/E ratio of 23.54, a PEG ratio of 1.37 and a beta of 1.04. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The stock has a fifty day moving average of $31.18 and a 200 day moving average of $38.18.
Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The company had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. Equities research analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have recently issued reports on the stock. Truist Financial reduced their target price on Astrana Health from $50.00 to $46.00 and set a "buy" rating on the stock in a report on Tuesday, March 18th. Barclays initiated coverage on Astrana Health in a report on Tuesday, April 1st. They set an "equal weight" rating and a $36.00 target price on the stock. Bank of America reduced their price target on shares of Astrana Health from $55.00 to $49.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Stifel Nicolaus lowered their price objective on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating for the company in a research report on Thursday, February 20th. Finally, Robert W. Baird reduced their target price on shares of Astrana Health from $86.00 to $50.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Astrana Health has an average rating of "Moderate Buy" and an average target price of $53.29.
Check Out Our Latest Analysis on Astrana Health
Astrana Health Profile
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Featured Articles
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
